PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		see Form PCT/ISA/220				
11669.237WOU1	ACTION	as well as, where applicable, item 5 below.					
International application No.	International filing date (day/month/year)		(Earliest) Priority Date (day/month/year)				
PCT/US2004/025247	04/08/2004		29/01/2004				
Applicant							
GENENTECH, INC.							
This International Search Report has beer according to Article 18. A copy is being tra			nority and is transmitted to the applicant				
This International Search Report consists	of a total of 8 sh	eets.					
X It is also accompanied by	a copy of each prior art document of	ited in this	report.				
Basis of the report a. With regard to the language, the i	nternational search was carried out	on the bas	is of the international application in the				
	ess otherwise indicated under this it						
The international states this Authority (Rul		of a transla	ation of the international application furnished to				
b. X With regard to any nucleo	tide and/or amino acid sequence	disclosed	in the international application, see Box No. I.				
2. X Certain claims were four	nd unsearchable (See Box II).						
3. X Unity of invention is lack	king (see Box III).						
4. With regard to the title ,							
the text is approved as sul	omitted by the applicant.		* * * * * * * * * * * * * * * * * * * *				
X the text has been establish	ned by this Authority to read as follo	ws:					
VARIANTS OF THE EXTRAC	ELLULAR DOMAIN OF BC	IA AND	USES THEREOF				
F. With regard to the abetmet							
5. With regard to the abstract, \[\sqrt{X} \] \text{ the text is approved as submitted by the applicant.}							
7		nis Authorit	y as it appears in Box No. IV. The applicant				
			th report, submit comments to this Authority.				
6. With regard to the drawings,							
a. the figure of the drawings to be published with the abstract is Figure No							
as suggested by the applicant.							
<u></u>	Authority, because the applicant fa	•	•				
	as selected by this Authority, because this figure better characterizes the invention.						
b. X none of the figures is to be	published with the abstract.						

International application No.

PCT/US2004/025247

Box	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With inven	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, the international search was carried out on the basis of:
	a.	type of material X a sequence listing table(s) related to the sequence listing
	b.	format of material X in written format X in computer readable form
	c.	ime of filing/furnishing X contained in the international application as filed filed together with the international application in computer readable form X furnished subsequently to this Authority for the purpose of search
2.	х	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addit	ional comments:

International application No. PCT/US2004/025247

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 41-50 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. X As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

BEST AVAILABLE COPY

10/587370

IAP11 Rec'd PCT/PTO 26 JUL 2006

International Application No. PCT/US2004 /025247

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7 (completely), 14 (completely), 16+17 (partially), 18+19 (completely), 22-35 (partially), 36 (completely), 38

(completely), 40 (partially), 41 (completely), 43-50 (partially)

Claims which relate to variants of the cysteine rich domain of BCMA wherein the ability to bind APRIL is retained or enhanced; nucleic acids encoding these variants; vectors and host cells comprising these nucleic acids; methods of using the variant polypeptides

2. claims: 8-13 (completely), 15 (completely), 16+17 (partially), 20+21 (completely), 22-35 (partially), 37 (completely), 39 (completely), 40 (partially), 42 (completely), 43-50 (partially)

Claims which relate to variants of the cysteine rich domain of BCMA wherein the ability to bind BAFF is retained or enhanced; nucleic acids encoding these variants; vectors and host cells comprising these nucleic acids; methods of using the variant polypeptides

International Application No

PCT/US2004/025247 a. classification of subject matter IPC 7 CO7K14/705 C12N C12N15/12A61K38/00 G01N33/50 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Belevant to claim No. P,X PATEL DARSHANA R ET AL: "Engineering an 1 - 50APRIL-specific B cell maturation antigen" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 16, 16 April 2004 (2004-04-16), pages 16727-16735, XP002318161 ISSN: 0021-9258 the whole document -/--BEST AVAILABLE COPY X Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but *A* document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention *E* earlier document but published on or after the international *X* document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the *O* document referring to an oral disclosure, use, exhibition or document is combined with one or more other, such docu ments, such combination being obvious to a person skilled in the art. document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report **0** 9 06. 2005 18 May 2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo ni, Fax: (+31–70) 340–3016

3

Weikl, M

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	In.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BODMER J-L ET AL: "The molecular architecture of the TNF superfamily" TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 27, no. 1, 1 January 2002 (2002-01-01), pages 19-26, XP004332356 ISSN: 0968-0004 cited in the application the whole document	1-7,14, 16-19, 22-36, 38,40, 41,43-50
A	GORDON NATHANIEL C ET AL: "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site." BIOCHEMISTRY, vol. 42, no. 20, 27 May 2003 (2003-05-27), pages 5977-5983, XP002318162 ISSN: 0006-2960 cited in the application page 5979, column 2, paragraph 3 - page 5981, column 2, paragraph 2; table 2	1-7,14, 16-19, 22-36, 38,40, 41,43-50
A	MACKAY FABIENNE ET AL: "The TNF family members BAFF and APRIL: The growing complexity." CYTOKINE AND GROWTH FACTOR REVIEWS, vol. 14, no. 3-4, 2003, pages 311-324, XP002318163 ISSN: 1359-6101 the whole document	1-7,14, 16-19, 22-36, 38,40, 41,43-50
A	WO 01/60397 A (GENENTECH, INC) 23 August 2001 (2001-08-23) claims 54-61	44-50
X	DATABASE UniProt 1 July 1993 (1993-07-01), "Tumor necrosis factor receptor superfamily member 17 (B-cell maturation antigen) BCMA" XP002328537 Database accession no. Q02223 abstract	8-13, 15-17, 20-35, 37,39, 40,42-50
x	LIU YINGFANG ET AL: "Ligand-receptor binding revealed by the TNF family member TALL-1." NATURE (LONDON), vol. 423, no. 6935, 1 May 2003 (2003-05-01), pages 49-56, XP002328536 ISSN: 0028-0836 page 52, column 1, paragraph 2 - page 52, column 2, paragraph 1	8-13, 15-17, 20-35, 37,39, 40,42-50
	-/	

3

International Application No
PCT/US2004/025247

Category °	etion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	 Relevant to claim No.
A	OREN D A ET AL: "Structural basis of BLyS receptor recognition" NATURE STRUCTURAL BIOLOGY, NEW YORK, NY, US, vol. 9, no. 4, April 2002 (2002-04), pages 288-292, XP002286033 ISSN: 1072-8368 the whole document	 8-13, 15-17, 20-35, 37,39, 40,42-50
	ISSN: 1072-8368	
;		

Information on patent family members

International Application No
PCT/US2004/025247

Patent document cited in search report		, and the same of		Patent family member(s)	Publication date
WO 0160397	A	23-08-2001	AU CA EP JP WO	2048501 A 2396793 A1 1255558 A1 2003522800 T 0160397 A1	27-08-2001 23-08-2001 13-11-2002 29-07-2003 23-08-2001

BEST AVAILABLE COPY